{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"description":"Bioverified 4-week continuous abstinence","groups":[{"description":"Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.\n\nbupropion hydrochloride: Given orally\n\nplacebo: Given orally","id":"OG000","title":"Arm I (1-week run-in)"},{"description":"Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.\n\nbupropion hydrochloride: Given orally","id":"OG001","title":"Arm II (4-week run-in)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Abstinence","type":"SECONDARY","unitOfMeasure":"Participants"}